Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Cooper (COO) Buys LifeGlobal To Widen Fertility Device Line

Published 04/03/2018, 10:35 PM
Updated 07/09/2023, 06:31 AM
The Cooper Companies, Inc.’s (NYSE:COO) CooperSurgical segment recently purchased The LifeGlobal Group assets for approximately $125 million.
Based in Connecticut, The LifeGlobal Group is a leading global provider of in-vitro fertilization (IVF) devices. The company recorded revenues of approximately $24 million in 2017 and it’s expected to grow mid- to-upper-single digits in the coming years. The transaction is likely to be neutral to earnings per share in fiscal 2018 and contribute thereafter.
Per management, the acquisition complements CooperSurgical’s fertility solution portfolio. It will further fortify Cooper’s position as a supplier of medical devices used by gynecologists and obstetricians.
CooperSurgical in Focus
CooperSurgical, one of the primary business segments of Cooper Companies, recorded revenues worth $145 million, which reflects a 32% year-over-year increase. Furthermore, the segment forayed outside the United States to become the largest IVF player globally through the acquisition of Denmark-based Origio.
Market Prospects
Per a research conducted by Allied Market Research, the IVF Services market generated revenues of $9,876 million in 2016 and is expected to reach $19.676 million by 2023, at a CAGR of 10.5% from 2017 to 2023.
Hence it can be concluded that the latest move by Cooper Companies has been a timely and strategic one.
Price Performance
In the past year, Cooper Companies’ shares have gained 12.2%, compared with the industry’s gain of 4.5%.
Zacks Rank & Key Picks
Cooper Companies carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are athenahealth, Inc. (NASDAQ:ATHN) , Bio-Rad Laboratories, Inc. (NYSE:BIO) and Centene Corporation (NYSE:CNC) . Each of these stocks sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
athenahealth has an expected long-term growth rate of 17.7% and projected earnings per share growth rate of 21.5%.
Bio-Rad has an expected long-term growth rate of 20% and projected earnings per share growth rate of 20%.
Centene has an expected long-term growth rate of 14.4% and projected earnings per share growth rate of 14.4%.
Wall Street’s Next Amazon (NASDAQ:AMZN)
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.


athenahealth, Inc. (ATHN): Free Stock Analysis Report

Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report

Centene Corporation (CNC): Free Stock Analysis Report

The Cooper Companies, Inc. (COO): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.